Circulating sphingolipids in heart failure

Frontiers in Cardiovascular Medicine

Cardiovascular Medicine

L. Ashley Cowart¹  Anna Kovilakath²  George Wohlford³ 

[1]Department of Biochemistry and Molecular Biology and the Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States

[2]Richmond Veteran's Affairs Medical Center, Richmond, VA, United States

[3]Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, United States

[4]Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, United States

关键词: sphingolipid;    ceramide;    heart failure;    HFrEF—heart failure with reduced ejection fraction;    HFpEF—heart failure with preserved ejection fraction;    serine palmitoyltransferase;    lipidomics;    ceramide score;   

DOI  :  10.3389/fcvm.2023.1154447

 received in 2023-01-30, accepted in 2023-04-04,  发布年份 2023

来源: Frontiers

【 摘 要 】

Lack of significant advancements in early detection and treatment of heart failure have precipitated the need for discovery of novel biomarkers and therapeutic targets. Over the past decade, circulating sphingolipids have elicited promising results as biomarkers that premonish adverse cardiac events. Additionally, compelling evidence directly ties sphingolipids to these events in patients with incident heart failure. This review aims to summarize the current literature on circulating sphingolipids in both human cohorts and animal models of heart failure. The goal is to provide direction and focus for future mechanistic studies in heart failure, as well as pave the way for the development of new sphingolipid biomarkers.

【 授权许可】

Unknown   
© 2023 Kovilakath, Wohlford and Cowart.